New omicron-specific COVID booster expected to be approved before trial data is in

The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.

The shots, modified to target the latest versions of the omicron variant, won’t have finished testing in humans when the FDA makes its decisions.

You May Also Like

MPs criticise award of Covid-19 contracts to medical company

The UK government’s “woefully inadequate record-keeping” means it is “impossible to have…

Labour scales back commitment to £28bn green plan

Shadow chancellor Rachel Reeves has scaled back the Labour party’s commitment to…

Russian troops retreat from front lines in southern Ukraine

Russia’s armed forces are retreating from the front lines in southern Ukraine…

Donald Trump’s legal drama features a strong cast of characters

The historic indictment of Donald Trump was the culmination of a four-year…